| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 35.41 | 16.4% | |
| Total Income | 35.52 | 16.1% | 5448.1% |
| Expenditure | 34.10 | 21.8% | 13677.3% |
| PBT | 1.42 | 45.4% | 261.7% |
| Net Profit | 1.06 | 58.6% | 170.1% |
| OPM | 3.78% | 4.21pp | |
| NPM | 2.99% | 5.40pp | 58.51pp |
| EPS | 0.45 | 58.3% | 114.3% |
Kabra Drugs Ltd: FY26 Net Loss After Tax ₹108.56 Lakhs
29 May 2026 · 29 May, 9:39 pm
Summary
Kabra Drugs Limited concluded the financial year 2026 with an audited Revenue from Operations of ₹9,274.00 Lakhs. For the fourth quarter of FY26, the company's revenue was ₹3,540.60 Lakhs, contributing to a Net Profit After Tax of ₹106.33 Lakhs. The full financial year, however, saw a Net Loss After Tax of ₹(108.51) Lakhs, despite a Profit Before Tax of ₹572.07 Lakhs, largely due to higher current tax expense following the transition to a new tax regime under Section 115BAA. The results also reflect adjustments for Ind AS 116, impacting depreciation and finance costs.
Key Highlights
- 1
Kabra Drugs Limited reported Revenue from Operations of ₹3,540.60 Lakhs for the quarter ended March 31, 2026.
- 2
The company recorded a Net Profit After Tax of ₹106.33 Lakhs for Q4 FY26, a significant increase from ₹39.36 Lakhs in the preceding quarter (Q3 FY26).
- 3
For the full financial year ended March 31, 2026, Revenue from Operations stood at ₹9,274.00 Lakhs.
- 4
Profit Before Tax for FY26 saw a substantial increase of 140.10% to ₹572.07 Lakhs, compared to ₹238.19 Lakhs in FY25.
- 5
Despite a strong Profit Before Tax of ₹572.07 Lakhs for FY26, the company reported a Net Loss After Tax of ₹(108.51) Lakhs, primarily due to higher tax expense from transitioning to a concessional tax regime under Section 115BAA.
- 6
EBITDA for Q4 FY26 was ₹145.24 Lakhs, yielding an EBITDA margin of 4.10% on revenue from operations.
Informational and educational content only. Not investment advice.